Generation of stem cell-derived β-cells from patients with type 1 diabetes

Jeffrey R. Millman, Chunhui Xie, Alana Van Dervort, Mads Gürtler, Felicia W. Pagliuca, Douglas A. Melton

Research output: Contribution to journalArticlepeer-review

299 Scopus citations


We recently reported the scalable in vitro production of functional stem cell-derived β-cells (SC-β cells). Here we extend this approach to generate the first SC-β cells from type 1 diabetic patients (T1D). β-cells are destroyed during T1D disease progression, making it difficult to extensively study them in the past. These T1D SC-β cells express β-cell markers, respond to glucose both in vitro and in vivo, prevent alloxan-induced diabetes in mice and respond to anti-diabetic drugs. Furthermore, we use an in vitro disease model to demonstrate the cells respond to different forms of β-cell stress. Using these assays, we find no major differences in T1D SC-β cells compared with SC-β cells derived from non-diabetic patients. These results show that T1D SC-β cells could potentially be used for the treatment of diabetes, drug screening and the study of β-cell biology.

Original languageEnglish
Article number11463
JournalNature communications
StatePublished - May 10 2016


Dive into the research topics of 'Generation of stem cell-derived β-cells from patients with type 1 diabetes'. Together they form a unique fingerprint.

Cite this